Literatur
-
1
Bloch R E, Lauterbach K, Oesingmann U. et al .
Beurteilungskriterien für Leitlinien in der medizinischen Versorgung - Beschlüsse der Vorstände der Bundesärztekammer und Kassenärztlicher Bundesvereinigung, Juni 1997.
Deutsches Ärzteblatt.
1997;
94
A2154/B-1831/C-1635
-
2 Phillips B, Ball C, Sackett D. Levels of evidence, http://www.cebm.net/index.aspx?o = 1025. Oxford. Centre for Evidence-based Medicine 2001
-
3 Abholz H H, Gillissen A, Magnussen H. et al .Nationale VersorgungsLeitlinie COPD, Langfassung, Version 1.2. In: Bundesärztekammer (BÄK) Arbeitsgemeinschaft der Deutschen Ärztekammern, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) 2006
-
4 Forsyth L, Graham K, Harbour R T. et al .SIGN 50: A guideline developers' handbook. Edinburgh: Scottish Intercollegiate Guidlines Network 2004
-
5 Bundesärztekammer (BÄK), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Kassenärztliche Bundesvereinigung (KBV) .Nationales Programm für Versorgungs-Leitlinien. Methoden-Report 2004
-
6
Tonnesen P, Carrozzi L, Fagerstrom K O. et al .
Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy.
Eur Respir J.
2007;
29
390-417
-
7
Vogelmeier C, Buhl R, Criée C P. et al .
Guidelines for the diagnosis and therapy of COPD issued by Deutsche Atemwegsliga and Deutsche Gesellschaft fur Pneumologie und Beatmungsmedizin.
Pneumologie.
2007;
61
1-40
-
8
Pauwels R A, Buist A S, Calverley P M. et al .
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.
Am J Respir Crit Care Med.
2001;
163
1256-1276
-
9
Rabe K F, Hurd S, Anzueto A. et al .
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.
Am J Respir Crit Care Med.
2007;
176
532-555
-
10
Aigner K, Homeier I, Koessler W. et al .
Standards der Raucherentwöhnung, Konsensus der ÖGP.
Wiener Klinische Wochenschrift.
2005;
117 Supplement 2
1-22
-
11 National Health Committee .Guidelines for Smoking Cessation. Wellington, New Zealand 2004
-
12
National Collaborating Centre for Chronic Conditions, (NICE) .
Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care.
Thorax.
2004;
59
1-232
-
13 West R, McNeill A, Raw M. Smoking Cessation Guidelines for Scotland: 2004 Update. In: NHS Health Scotland and ASH Scotland 2004
-
14 Batra A, Lindinger P, Schütz C. Tabakbedingte Störungen „Leitlinie Tabakentwöhnung”. In: Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften 2004
-
15
Anderson J E, Jorenby D E, Scott W J. et al .
Treating Tobacco Use and Dependence: An Evidence-Based Clinical Practice Guideline for Tobacco Cessation.
Chest.
2002;
121
932-941
-
16 Orsetti K. Smoking Cessation Guideline. In: University of Michigan Health System 2001
-
17
Bundesärztekammer, Kassenärztliche Bundesvereinigung .
Checkliste Methodische Qualität von Leitlinien, 2. Version (8/1999).
Deutsches Ärzteblatt.
2000;
97
A1170
-
18
Parrott S, Godfrey C.
Economics of smoking cessation.
Bmj.
2004;
328
947-949
-
19
Fiore M C.
Treating tobacco use and dependence: an introduction to the US Public Health Service Clinical Practice Guideline.
Respir Care.
2000;
45
1196-1199
-
20 U.S. Department of Health and Human Services .Reducing Tobacco Use: A Report of the Surgeon General. Atlanta, Georgia: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health 2000
-
21 Rosser W, Tremblay M. Smoking Cessation Guidelines. In: Pegasus Healthcare International 2000
-
22
West R, McNeill A, Raw M.
Smoking cessation guidelines for health professionals: an update. Health Education Authority.
Thorax.
2000;
55
987-999
-
23
Parrott S, Godfrey C, Raw M. et al .
Guidance for commissioners on the cost effectiveness of smoking cessation interventions. Health Educational Authority.
Thorax.
1998;
53 Suppl 5
S1-38
-
24
Raw M, McNeill A, West R.
Smoking Cessation Guidelines for Health Professionals - A guide to effective smoking cessation interventions for the health care system.
Thorax.
1998;
53
1-18
-
25
Arzneimittelkommission der deutschen Ärzteschaft .
Empfehlungen zur Therapie der Tabakabhängigkeit.
Suchtmed.
2001;
3
156-175
-
26 Hoch E, Mühlig S, Nowak D. et al .Rauchen und Nikotinabhängigkeit in Deutschland: Eine klinisch-epidemiologische Perspektive. Zeitschrift für klinische Psychologie und Psychotherapie (in press)
-
27
Lampert T, Burger M.
Verbreitung und Strukturen des Tabakkonsums in Deutschland.
Bundesgesundheitsbl - Gesundheitsforsch - Gesundheitsschutz.
2005;
48
1231-1241
-
28
Janson C, Kunzli N, de Marco R. et al .
Changes in active and passive smoking in the European Community Respiratory Health Survey.
Eur Respir J.
2006;
27
517-524
-
29
Miller C H, Burgoon M, Grandpre J R. et al .
Identifying principal risk factors for the initiation of adolescent smoking behaviors: the significance of psychological reactance.
Health Commun.
2006;
19
241-252
-
30
Schumann A, Hapke U, Meyer C. et al .
Prevalence, characteristics, associated mental disorders and predictors of DSM-IV nicotine dependence.
Eur Addict Res.
2004;
10
29-34
-
31
Rounsaville B J, Bryant K, Babor T. et al .
Cross system agreement for substance use disorders: DSM-III-R, DSM-IV and ICD-10.
Addiction.
1993;
88
337-348
-
32
Watkins S S, Koob G F, Markou A.
Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal.
Nicotine Tob Res.
2000;
2
19-37
-
33
Di Chiara G, Imperato A.
Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats.
Proc Natl Acad Sci U S A.
1988;
85
5274-5278
-
34
Balfour D J.
Neural mechanisms underlying nicotine dependence.
Addiction.
1994;
89
1419-1423
-
35
Dani J A, Heinemann S.
Molecular and cellular aspects of nicotine abuse.
Neuron.
1996;
16
905-908
-
36
Corrigall W A, Franklin K B, Coen K M. et al .
The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine.
Psychopharmacology (Berl).
1992;
107
285-289
-
37
Nelson C B, Wittchen H U.
Smoking and nicotine dependence. Results from a sample of 14- to 24-year-olds in Germany.
Eur Addict Res.
1998;
4
42-49
-
38
Centers for Disease Control and Prevention (CDC) .
Cigarette smoking among adults - United States, 1995.
MMWR Morb Mortal Wkly Rep.
1997;
46
1217-1220
-
39
West R, Sohal T.
“Catastrophic” pathways to smoking cessation: findings from national survey.
Bmj.
2006;
332
458-460
-
40
Hughes J R, Hatsukami D.
Signs and symptoms of tobacco withdrawal.
Arch Gen Psychiatry.
1986;
43
289-294
-
41
Le Foll B, Goldberg S R.
Nicotine as a typical drug of abuse in experimental animals and humans.
Psychopharmacology (Berl).
2006;
184
367-381
-
42
Malin D H, Lake J R, Carter V A. et al .
Naloxone precipitates nicotine abstinence syndrome in the rat.
Psychopharmacology (Berl).
1993;
112
339-342
-
43
Epping-Jordan M P, Watkins S S, Koob G F. et al .
Dramatic decreases in brain reward function during nicotine withdrawal.
Nature.
1998;
393
76-79
-
44
Benwell M E, Balfour D J, Anderson J M.
Evidence that tobacco smoking increases the density of (-)-[3H]nicotine binding sites in human brain.
J Neurochem.
1988;
50
1243-1247
-
45
Breese C R, Marks M J, Logel J. et al .
Effect of smoking history on [3H]nicotine binding in human postmortem brain.
J Pharmacol Exp Ther.
1997;
282
7-13
-
46
Perry D C, Davila-Garcia M I, Stockmeier C A. et al .
Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies.
J Pharmacol Exp Ther.
1999;
289
1545-1552
-
47
Benwell M E, Balfour D J.
Effects of nicotine administration and its withdrawal on plasma corticosterone and brain 5-hydroxyindoles.
Psychopharmacology (Berl).
1979;
63
7-11
-
48
Benwell M E, Balfour D J.
The effects of nicotine administration on 5-HT uptake and biosynthesis in rat brain.
Eur J Pharmacol.
1982;
84
71-77
-
49
Fidler J A, Wardle J, Brodersen N H. et al .
Vulnerability to smoking after trying a single cigarette can lie dormant for three years or more.
Tob Control.
2006;
15
205-209
-
50
Church D F, Pryor W A.
Free-radical chemistry of cigarette smoke and its toxicological implications.
Environ Health Perspect.
1985;
64
111-126
-
51 Church D F, Pryor W A. The oxidative stress placed on the lung by cigarette smoke. In: Crystal RG, West JB (eds). The Lung NY: Raven Press 1991: 1975-1979
-
52
MacNee W, Wiggs B, Belzberg A S. et al .
The effect of cigarette smoking on neutrophil kinetics in human lungs.
N Engl J Med.
1989;
321
924-928
-
53
Nadel J A.
Role of neutrophil elastase in hypersecretion during COPD exacerbations, and proposed therapies.
Chest.
2000;
117
386S-389S
-
54
Walsh D E, Greene C M, Carroll T P. et al .
Interleukin-8 up-regulation by neutrophil elastase is mediated by MyD88/IRAK/TRAF-6 in human bronchial epithelium.
J Biol Chem.
2001;
276
35 494-35 499
-
55
Shapiro S D.
Diverse roles of macrophage matrix metalloproteinases in tissue destruction and tumor growth.
Thromb Haemost.
1999;
82
846-849
-
56
Arcavi L, Benowitz N L.
Cigarette smoking and infection.
Arch Intern Med.
2004;
164
2206-2216
-
57
Dye J A, Adler K B.
Effects of cigarette smoke on epithelial cells of the respiratory tract.
Thorax.
1994;
49
825-834
-
58
Marcy T W, Merrill W W.
Cigarette smoking and respiratory tract infection.
Clin Chest Med.
1987;
8
381-391
-
59
Kalra R, Singh S P, Savage S M. et al .
Effects of cigarette smoke on immune response: chronic exposure to cigarette smoke impairs antigen-mediated signaling in T cells and depletes IP3-sensitive Ca(2+) stores.
J Pharmacol Exp Ther.
2000;
293
166-171
-
60
Gerrard J W, Heiner D C, Ko C G. et al .
Immunoglobulin levels in smokers and non-smokers.
Ann Allergy.
1980;
44
261-262
-
61 U.S. Department of Health and Human Services .The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health 2004
-
62
Lebowitz M D.
Smoking habits and changes in smoking habits as they relate to chronic conditions and respiratory symptoms.
Am J Epidemiol.
1977;
105
534-543
-
63
Walraven G E, Nyan O A, Sande M A van der. et al .
Asthma, smoking and chronic cough in rural and urban adult communities in The Gambia.
Clin Exp Allergy.
2001;
31
1679-1685
-
64
Troisi R J, Speizer F E, Rosner B. et al .
Cigarette smoking and incidence of chronic bronchitis and asthma in women.
Chest.
1995;
108
1557-1561
-
65
Pilotto L S, Smith B J, Nitschke M. et al .
Industry, air quality, cigarette smoke and rates of respiratory illness in Port Adelaide.
Aust N Z J Public Health.
1999;
23
657-660
-
66
Tobacco smoking.
IARC Monogr Eval Carcinog Risk Chem Hum.
1986;
38
35-394
-
67
Doll R, Hill A B.
The mortality of doctors in relation to their smoking habits; a preliminary report.
Br Med J.
1954;
1
1451-1455
-
68
Bouchardy C, Benhamou S, Jourenkova N. et al .
Metabolic genetic polymorphisms and susceptibility to lung cancer.
Lung Cancer.
2001;
32
109-112
-
69
Doll R, Peto R, Boreham J. et al .
Mortality in relation to smoking: 50 years' observations on male British doctors.
Bmj.
2004;
328
1519
-
70
Piipari R, Jaakkola J J, Jaakkola N. et al .
Smoking and asthma in adults.
Eur Respir J.
2004;
24
734-739
-
71
Senthilselvan A, Chen Y, Dosman J A.
Predictors of asthma and wheezing in adults. Grain farming, sex, and smoking.
Am Rev Respir Dis.
1993;
148
667-670
-
72
Godtfredsen N S, Lange P, Prescott E. et al .
Changes in smoking habits and risk of asthma: a longitudinal population based study.
Eur Respir J.
2001;
18
549-554
-
73
Eisner M D, Klein J, Hammond S K. et al .
Directly measured second hand smoke exposure and asthma health outcomes.
Thorax.
2005;
60
814-821
-
74
Gilliland F D, Islam T, Berhane K. et al .
Regular smoking and asthma incidence in adolescents.
Am J Respir Crit Care Med.
2006;
174
1094-1100
-
75
Genuneit J, Weinmayr G, Radon K. et al .
Smoking and the incidence of asthma during adolescence: results of a large cohort study in Germany.
Thorax.
2006;
61
572-578
-
76
Piitulainen E, Sveger T.
Effect of environmental and clinical factors on lung function and respiratory symptoms in adolescents with alpha1-antitrypsin deficiency.
Acta Paediatr.
1998;
87
1120-1124
-
77
Braman S S.
Chronic cough due to chronic bronchitis: ACCP evidence-based clinical practice guidelines.
Chest.
2006;
129
104S-115S
-
78
Andersen A, Berge S R, Engeland A. et al .
Exposure to nickel compounds and smoking in relation to incidence of lung and nasal cancer among nickel refinery workers.
Occup Environ Med.
1996;
53
708-713
-
79
Blake G H, Abell T D, Stanley W G.
Cigarette smoking and upper respiratory infection among recruits in basic combat training.
Ann Intern Med.
1988;
109
198-202
-
80
Cohen S, Tyrrell D A, Russell M A. et al .
Smoking, alcohol consumption, and susceptibility to the common cold.
Am J Public Health.
1993;
83
1277-1283
-
81
Plaschke P P, Janson C, Norrman E. et al .
Onset and remission of allergic rhinitis and asthma and the relationship with atopic sensitization and smoking.
Am J Respir Crit Care Med.
2000;
162
920-924
-
82
Nuorti J P, Butler J C, Farley M M. et al .
Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team.
N Engl J Med.
2000;
342
681-689
-
83
Almirall J, Gonzalez C A, Balanzo X. et al .
Proportion of community-acquired pneumonia cases attributable to tobacco smoking.
Chest.
1999;
116
375-379
-
84
Straus W L, Plouffe J F, File Jr T M. et al .
Risk factors for domestic acquisition of legionnaires disease. Ohio legionnaires Disease Group.
Arch Intern Med.
1996;
156
1685-1692
-
85
Kark J D, Lebiush M, Rannon L.
Cigarette smoking as a risk factor for epidemic a(h1n1) influenza in young men.
N Engl J Med.
1982;
307
1042-1046
-
86
Buskin S E, Gale J L, Weiss N S. et al .
Tuberculosis risk factors in adults in King County, Washington, 1988 through 1990.
Am J Public Health.
1994;
84
1750-1756
-
87
Alcaide J, Altet M N, Plans P. et al .
Cigarette smoking as a risk factor for tuberculosis in young adults: a case-control study.
Tuber Lung Dis.
1996;
77
112-116
-
88
Ryu J H, Colby T V, Hartman T E. et al .
Smoking-related interstitial lung diseases: a concise review.
Eur Respir J.
2001;
17
122-132
-
89
Katzenstein A L, Myers J L.
Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification.
Am J Respir Crit Care Med.
1998;
157
1301-1315
-
90
Coultas D B, Zumwalt R E, Black W C. et al .
The epidemiology of interstitial lung diseases.
Am J Respir Crit Care Med.
1994;
150
967-972
-
91
Johnston I D, Prescott R J, Chalmers J C. et al .
British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society.
Thorax.
1997;
52
38-44
-
92
Marshall R P, Puddicombe A, Cookson W O. et al .
Adult familial cryptogenic fibrosing alveolitis in the United Kingdom.
Thorax.
2000;
55
143-146
-
93
Schwartz D A, Merchant R K, Helmers R A. et al .
The influence of cigarette smoking on lung function in patients with idiopathic pulmonary fibrosis.
Am Rev Respir Dis.
1991;
144
504-506
-
94
Baumgartner K B, Samet J M, Stidley C A. et al .
Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis.
Am J Respir Crit Care Med.
1997;
155
242-248
-
95
Hubbard R, Venn A, Lewis S. et al .
Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study.
Am J Respir Crit Care Med.
2000;
161
5-8
-
96
Hartman T E, Primack S L, Kang E Y. et al .
Disease progression in usual interstitial pneumonia compared with desquamative interstitial pneumonia. Assessment with serial CT.
Chest.
1996;
110
378-382
-
97
Yousem S A, Colby T V, Gaensler E A.
Respiratory bronchiolitis-associated interstitial lung disease and its relationship to desquamative interstitial pneumonia.
Mayo Clin Proc.
1989;
64
1373-1380
-
98
Niewoehner D E, Kleinerman J, Rice D B.
Pathologic changes in the peripheral airways of young cigarette smokers.
N Engl J Med.
1974;
291
755-758
-
99
Myers J L, Veal C C F, Shin M S. et al .
Respiratory bronchiolitis causing interstitial lung disease. A clinicopathologic study of six cases.
Am Rev Respir Dis.
1987;
135
880-884
-
100
Favara B E, Feller A C, Pauli M. et al .
Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society.
Med Pediatr Oncol.
1997;
29
157-166
-
101
Hance A J, Basset F, Saumon G. et al .
Smoking and interstitial lung disease. The effect of cigarette smoking on the incidence of pulmonary histiocytosis X and sarcoidosis.
Ann N Y Acad Sci.
1986;
465
643-656
-
102
Casolaro M A, Bernaudin J F, Saltini C. et al .
Accumulation of Langerhans' cells on the epithelial surface of the lower respiratory tract in normal subjects in association with cigarette smoking.
Am Rev Respir Dis.
1988;
137
406-411
-
103
Westedt M L, Hazes J M, Breedveld F C. et al .
Cigarette smoking and pulmonary diffusion defects in rheumatoid arthritis.
Rheumatol Int.
1998;
18
1-4
-
104
Wolfe F.
The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis.
J Rheumatol.
2000;
27
630-637
-
105
Banks J, Banks C, Cheong B. et al .
An epidemiological and clinical investigation of pulmonary function and respiratory symptoms in patients with rheumatoid arthritis.
Q J Med.
1992;
85
795-806
-
106
Hyland R H, Gordon D A, Broder I. et al .
A systematic controlled study of pulmonary abnormalities in rheumatoid arthritis.
J Rheumatol.
1983;
10
395-405
-
107
Merkel F, Pullig O, Marx M. et al .
Course and prognosis of anti-basement membrane antibody (anti-BM-Ab)-mediated disease: report of 35 cases.
Nephrol Dial Transplant.
1994;
9
372-376
-
108
Kelly P T, Haponik E F.
Goodpasture syndrome: molecular and clinical advances.
Medicine (Baltimore).
1994;
73
171-185
-
109
Pauwels R A, Rabe K F.
Burden and clinical features of chronic obstructive pulmonary disease (COPD).
Lancet.
2004;
364
613-620
-
110
Murray C J, Lopez A D.
Alternative projections of mortality and disability by cause 1990 - 2020: Global Burden of Disease Study.
Lancet.
1997;
349
1498-1504
-
111
Behr J, Nowak D.
Tobacco smoke and respiratory disease.
In: d'Amato G, Holgate S (eds). European Respiratory Monograph (7) The impact of air pollution on respiratory health.
ERS.
2002;
21
161-179
-
112 European Commission .Tobacco or Health in the European Union - past, present and future. The ASPECT Consortium. Luxembourg: Office for Official Publications of the European Communities 2004
-
113
Shahab L, Jarvis M J, Britton J R. et al .
Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample.
Thorax.
2006;
61
1043-1047
-
114 Criée C P, Novak D. Einsparpotential durch Prävention bei COPD. In: Schauder P, Berthold H, Eckel H, Ollenschläger G (eds). Zukunft sichern: Senkung der Zahl chronisch Kranker, Verwirklichung einer realistischen Utopie. Köln: Deutscher Ärzteverlag 2006: 205-208
-
115
de Marco R, Accordini S, Cerveri I. et al .
An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages.
Thorax.
2004;
59
120-125
-
116
Chapman K R, Mannino D M, Soriano J B. et al .
Epidemiology and costs of chronic obstructive pulmonary disease.
Eur Respir J.
2006;
27
188-207
-
117
Nowak D, Berger K, Lippert B. et al .
Epidemiology and health economics of COPD across Europe: a critical analysis.
Treat Respir Med.
2005;
4
381-395
-
118
Buist A S, McBurnie M A, Vollmer W M. et al .
International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study.
Lancet.
2007;
370
741-750
-
119
Burney P.
The pharmacoepidemiology of COPD: Recent advances and methodological discussion.
Eur Respir J.
2003;
22
1S-44S
-
120
Lundback B, Lindberg A, Lindstrom M. et al .
Not 15 but 50 % of smokers develop COPD? - Report from the Obstructive Lung Disease in Northern Sweden Studies.
Respir Med.
2003;
97
115-122
-
121
Wedzicha J A, Donaldson G C.
Exacerbations of chronic obstructive pulmonary disease.
Respir Care.
2003;
48
1204-1213; discussion 1213 - 1205
-
122
Lundback B, Gulsvik A, Albers M. et al .
Epidemiological aspects and early detection of chronic obstructive airway diseases in the elderly.
Eur Respir J Suppl.
2003;
40
3s-9s
-
123
Lokke A, Lange P, Scharling H. et al .
Developing COPD: a 25 year follow up study of the general population.
Thorax.
2006;
61
935-939
-
124
Prescott E, Bjerg A M, Andersen P K. et al .
Gender difference in smoking effects on lung function and risk of hospitalization for COPD: results from a Danish longitudinal population study.
Eur Respir J.
1997;
10
822-827
-
125
Xu X, Li B, Wang L.
Gender difference in smoking effects on adult pulmonary function.
Eur Respir J.
1994;
7
477-483
-
126
Chapman K R.
Chronic obstructive pulmonary disease: are women more susceptible than men?.
Clinics in Chest Medicine.
2004;
25
331-341
-
127
Cookson W O.
State of the art. Genetics and genomics of chronic obstructive pulmonary disease.
Proc Am Thorac Soc.
2006;
3
473-475
-
128
Rennard S I, Vestbo J.
COPD: the dangerous underestimate of 15 %.
Lancet.
2006;
367
1216-1219
-
129
Falk G A, Briscoe W A.
Alpha-1-antitrypsin deficiency in chronic obstructive pulmonary disease.
Ann Intern Med.
1970;
72
427-429
-
130
Wouters E F.
Chronic obstructive pulmonary disease. 5: systemic effects of COPD.
Thorax.
2002;
57
1067-1070
-
131
Reid M B.
COPD as a muscle disease.
Am J Respir Crit Care Med.
2001;
164
1101-1102
-
132
Anthonisen N R, Skeans M A, Wise R A. et al .
The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial.
Ann Intern Med.
2005;
142
233-239
-
133
Andreas S, Anker S D, Scanlon P D. et al .
Neurohumoral activation as a link to systemic manifestation of chronic lung disease.
Chest.
2005;
128
3618-3624
-
134
Yanbaeva D G, Dentener M A, Creutzberg E C. et al .
Systemic Effects of Smoking.
Chest.
2007;
131
1557-1566
-
135
Cerveri I, Accordini S, Corsico A. et al .
Chronic cough and phlegm in young adults.
Eur Respir J.
2003;
22
413-417
-
136
Vestbo J, Prescott E, Lange P.
Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group.
Am J Respir Crit Care Med.
1996;
153
1530-1535
-
137
Kerstjens H A, Rijcken B, Schouten J P. et al .
Decline of FEV1 by age and smoking status: facts, figures, and fallacies.
Thorax.
1997;
52
820-827
-
138
Fletcher C, Peto R.
The natural history of chronic airflow obstruction.
Br Med J.
1977;
1
1645-1648
-
139
Gold D R, Wang X, Wypij D. et al .
Effects of cigarette smoking on lung function in adolescent boys and girls.
N Engl J Med.
1996;
335
931-937
-
140
Sherrill D L, Lebowitz M D, Knudson R J. et al .
Smoking and symptom effects on the curves of lung function growth and decline.
Am Rev Respir Dis.
1991;
144
17-22
-
141
Xu X, Weiss S T, Rijcken B. et al .
Smoking, changes in smoking habits, and rate of decline in FEV1: new insight into gender differences.
Eur Respir J.
1994;
7
1056-1061
-
142
Anthonisen N R.
Lung Health Study.
Am Rev Respir Dis.
1989;
140
871-872
-
143
Anthonisen N R, Connett J E, Enright P L. et al .
Hospitalizations and mortality in the Lung Health Study.
Am J Respir Crit Care Med.
2002;
166
333-339
-
144
Anthonisen N R, Lindgren P G, Tashkin D P. et al .
Bronchodilator response in the lung health study over 11 yrs.
Eur Respir J.
2005;
26
45-51
-
145
Scanlon P D, Connett J E, Waller L A. et al .
Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study.
Am J Respir Crit Care Med.
2000;
161
381-390
-
146
Viegi G, Paoletti P, Carrozzi L. et al .
CO diffusing capacity in a general population sample: relationships with cigarette smoking and airflow obstruction.
Respiration.
1993;
60
155-161
-
147
Viegi G, Sherrill D L, Carrozzi L. et al .
An 8-year follow-up of carbon monoxide diffusing capacity in a general population sample of northern italy.
Chest.
2001;
120
74-80
-
148
Verbanck S, Schuermans D, Paiva M. et al .
Small airway function improvement after smoking cessation in smokers without airway obstruction.
Am J Respir Crit Care Med.
2006;
174
853-857
-
149
Willemse B W, Postma D S, Timens W. et al .
The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation.
Eur Respir J.
2004;
23
464-476
-
150
Willemse B W, ten Hacken N H, Rutgers B. et al .
Smoking cessation improves both direct and indirect airway hyperresponsiveness in COPD.
Eur Respir J.
2004;
24
391-396
-
151
Magnussen H, Goeckenjan G, Kohler D. et al .
Guidelines to long-term oxygen therapy.
Pneumologie.
2001;
55
454-464
-
152
Lacasse Y, LaForge J, Maltais F.
Got a match? Home oxygen therapy in current smokers.
Thorax.
2006;
61
374-375
-
153
Heidrich J, Wellmann J, Heuschmann P U. et al .
Mortality and morbidity from coronary heart disease attributable to passive smoking.
Eur Heart J.
2007;
28
2498-2502
-
154 European Respiratory Society .Lifting the smokescreen. Brussels: European Respiratory Society 2006
-
155
Jaakkola M S, Jaakkola J J.
Impact of smoke-free workplace legislation on exposures and health: possibilities for prevention.
Eur Respir J.
2006;
28
397-408
-
156
Lam T H, Ho L M, Hedley A J. et al .
Secondhand smoke and respiratory ill health in current smokers.
Tob Control.
2005;
14
307-314
-
157
Raupach T, Radon K, Nowak D. et al .
Passive Smoking - Health Consequences and Effects of Exposure Prevention.
Pneumologie.
2008;
62
44-50
-
158
Jimenez-Ruiz C A, Masa F, Miravitlles M. et al .
Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD.
Chest.
2001;
119
1365-1370
-
159
Jimenez-Ruiz C, Miravitlles M, Sobradillo V. et al .
Can cumulative tobacco consumption, FTND score, and carbon monoxide concentration in expired air be predictors of chronic obstructive pulmonary disease?.
Nicotine Tob Res.
2004;
6
649-653
-
160
Hertzen L von, Reunanen A, Impivaara O. et al .
Airway obstruction in relation to symptoms in chronic respiratory disease - a nationally representative population study.
Respiratory Medicine.
2000;
94
356-363
-
161
Medici T C, Unger S, Ruegger M.
Smoking pattern of smokers with and without tobacco-smoke-related lung diseases.
Am Rev Respir Dis.
1985;
131
385-388
-
162
Killen J, Fortmann S, Kraemer H. et al .
Who will relapse? Symptoms of nicotine dependence predict long-term relapse after smoking cessation.
J Consult Clin Psychol.
1992;
60
797-801
-
163
Clark K D, Wardrobe-Wong N, Elliott J J. et al .
Cigarette smoke inhalation and lung damage in smoking volunteers.
Eur Respir J.
1998;
12
395-399
-
164
Wagena E J, Huibers M J, Schayck C P van.
Antidepressants in the treatment of patients with COPD: possible associations between smoking cigarettes, COPD and depression.
Thorax.
2001;
56
587-588
-
165
Manen J G van, Bindels P JE, Dekker F W. et al .
Risk of depression in patients with chronic obstructive pulmonary disease and its determinants.
Thorax.
2002;
57
412-416
-
166
Wagena E J, Meer R M van der, Ostelo R J. et al .
The efficacy of smoking cessation strategies in people with chronic obstructive pulmonary disease: results from a systematic review.
Respir Med.
2004;
98
805-815
-
167
Yohannes A M, Roomi J, Baldwin R C. et al .
Depression in elderly outpatients with disabling chronic obstructive pulmonary disease.
Age and Ageing.
1998;
27
155-160
-
168
Dudley D, Glaser E, Jorgenson B. et al .
Psychosocial concomitants to rehabilitation in chronic obstructive pulmonary disease. 3. Dealing with psychiatric disease (as distinguished from psychosocial or psychophysiologic problems).
Chest.
1980;
77
667
-
169
Isoaho R, Puolijoki H, Huhti E. et al .
Chronic obstructive pulmonary disease and self-maintaining functions in the elderly - a population-based study.
Scand J Prim Health Care.
1995;
13
122-127
-
170
O'Neill E.
Illness representations and coping of women with chronic obstructive pulmonary disease: a pilot study.
Heart Lung.
2002;
31
295-302
-
171
DiMarco F, Verga M, Reggente M. et al .
Anxiety and depression in COPD patients: The roles of gender and disease severity.
Respir Med.
2006;
100
1767-1774
-
172
Ng T P, Niti M, Tan W C. et al .
Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life.
Arch Intern Med.
2007;
167
60-67
-
173 Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2004: CD000031
-
174
Breslau N, Johnson E O, Hiripi E. et al .
Nicotine Dependence in the United States - Prevalence, Trends, and Smoking Persistence.
Arch Gen Psychiatry.
2001;
58
810-816
-
175
Glassman A H, Covey L S, Stetner F. et al .
Smoking cessation and the course of major depression: a follow-up study.
Lancet.
2001;
357
1929-1932
-
176
Breslau N, Peterson E L, Schultz L R. et al .
Major Depression and Stages of Smoking.
A Longitudinal Investigation.
1998;
55
161-166
-
177
Dierker L, Avenevoli S, Stolar M. et al .
Smoking and depression: an examination of mechanisms of comorbidity.
Am J Psychiatry.
2002;
159
947-953
-
178
Covey L, Glassman A, Stetner F.
Cigarette smoking and major depression.
J Addict Dis.
1998;
17
35-46
-
179
Wilhelm K, Arnold K, Niven H. et al .
Grey lungs and blue moods: smoking cessation in the context of lifetime depression history.
Aust N Z J Psychiatry.
2004;
38
896-905
-
180
Breslau N.
Psychiatric comorbidity of smoking and nicotine dependence.
Behav Genet.
1995;
25
95-101
-
181
John U, Meyer C, Rumpf H J. et al .
Smoking, nicotine dependence and psychiatric comorbidity - a population-based study including smoking cessation after three years.
Drug Alcohol Depend.
2004;
76
287-295
-
182
Haug N A, Heinberg L J, Guarda A S.
Cigarette smoking and its relationship to other substance use among eating disordered inpatients.
Eat Weight Disord.
2001;
6
130-139
-
183
Kordon A, Kahl K G.
Attention-deficit/hyperactivity disorder (ADHS) in adulthood.
Psychother Psychosom Med Psychol.
2004;
54
124-136
-
184
Anthonisen N R, Connett J E, Murray R P.
Smoking and lung function of Lung Health Study participants after 11 years.
Am J Respir Crit Care Med.
2002;
166
675-679
-
185
Heatherton T F, Kozlowski L T, Frecker R C. et al .
The Fagerstrom-Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire.
Br J Addict.
1991;
86
1119-1127
-
186
Anda R F, Williamson D F, Escobedo L G. et al .
Depression and the dynamics of smoking. A national perspective.
Jama.
1990;
264
1541-1545
-
187
Killen J D, Fortmann S P, Kraemer H C. et al .
Interactive effects of depression symptoms, nicotine dependence, and weight change on late smoking relapse.
J Consult Clin Psychol.
1996;
64
1060-1067
-
188
Herrmann C, Buss U.
Vorstellung und Validierung einer deutschen Version der „Hospital Anxiety and Depression Scale” (HAD-Skala); ein Fragebogen zur Erfassung des psychischen Befindens bei Patienten mit körperlichen Beschwerden.
Diagnostica.
1994;
40
143-154
-
189 Löwe B. PHQ-D - Gesundheitsfragebogen für Patienten. In: Schumacher J, Strauss B (eds). Klinische Interviews und Ratingskalen Göttingen: Hogrefe 2004: 321-327
-
190 Riemann K, Gerber U. Standardisierung von Fragestellungen zum Rauchen: ein Beitrag zur Qualitätssicherung in der Präventionsforschung. 4 ed: BZgA. Köln: Bundeszentrale für gesundheitliche Aufklärung 2000
-
191
Hilberink S R, Jacobs J E, Schlosser M. et al .
Characteristics of patients with COPD in three motivational stages related to smoking cessation.
Patient Educ Couns.
2006;
61
449-457
-
192 Bize R, Burnand B, Mueller Y. et al .Biomedical risk assessment as an aid for smoking cessation. Cochrane Database Syst Rev 2005: CD004705
-
193
West R, Hajek P, Stead L. et al .
Outcome criteria in smoking cessation trials: proposal for a common standard.
Addiction.
2005;
100
299-303
-
194
Brandt C J, Ellegaard H, Joensen M. et al .
Effect of diagnosis of “smoker's lung”. RYLUNG Group.
Lancet.
1997;
349
253
-
195
Humerfelt S, Eide G E, Kvåle G. et al .
Effectiveness of postal smoking cessation advice: a randomized controlled trial in young men with reduced FEV1 and asbestos exposure.
Eur Respir J.
1998;
11
284-290
-
196
Walters N, Coleman T.
Comparison of the smoking behaviour and attitudes of smokers who attribute respiratory symptoms to smoking with those who do not.
Br J Gen Pract.
2002;
52
132-134
-
197
Bednarek M, Gorecka D, Wielgomas J. et al .
Smokers with airway obstruction are more likely to quit smoking.
Thorax.
2006;
61
869-73
-
198
Gorecka D, Bednarek M, Nowinski A. et al .
Diagnosis of airflow limitation combined with smoking cessation advice increases stop-smoking rate.
Chest.
2003;
123
1916-1923
-
199
Townsend C O, Clark M M, Jett J R. et al .
Relation between smoking cessation and receiving results from three annual spiral chest computed tomography scans for lung carcinoma screening.
Cancer.
2005;
103
2154-2162
-
200
A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report.
Jama.
2000;
283
3244-3254
-
201
Soria R, Legido A, Escolano C. et al .
A randomised controlled trial of motivational interviewing for smoking cessation.
Br J Gen Pract.
2006;
56
768-774
-
202
Miller W R.
Motivational interviewing: research, practice, and puzzles.
Addict Behav.
1996;
21
835-842
-
203
O'Hara P, Grill J, Rigdon M A. et al .
Design and results of the initial intervention program for the Lung Health Study. The Lung Health Study Research Group.
Prev Med.
1993;
22
304-315
-
204
Anthonisen N R, Connett J E, Kiley J P. et al .
Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study.
Jama.
1994;
272
1497-1505
-
205
Godtfredsen N S, Vestbo J, Osler M. et al .
Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study.
Thorax.
2002;
57
967-972
-
206
Kanner R E, Anthonisen N R, Connett J E.
Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study.
Am J Respir Crit Care Med.
2001;
164
358-364
-
207
Jo Y H, Talmage D A, Role L W.
Nicotinic receptor-mediated effects on appetite and food intake.
J Neurobiol.
2002;
53
618-632
-
208
Williamson D F, Madans J, Anda R F. et al .
Smoking cessation and severity of weight gain in a national cohort.
N Engl J Med.
1991;
324
739-745
-
209
Flegal K M, Troiano R P, Pamuk E R. et al .
The influence of smoking cessation on the prevalence of overweight in the United States.
N Engl J Med.
1995;
333
1165-1170
-
210 Carroll M E, Meisch R A. Increased drug-reinforced behaviour due to food deprivation. In: Thompson T, Dews PB, JE B (eds). Advances in Behavioural Pharmacology. Orlando: Academic Press Inc 1984: 47-88
-
211
Swan G E, Carmelli D.
Characteristics associated with excessive weight gain after smoking cessation in men.
Am J Public Health.
1995;
85
73-77
-
212
Pomerleau C S, Zucker A N, Stewart A J.
Characterizing concerns about post-cessation weight gain: results from a national survey of women smokers.
Nicotine Tob Res.
2001;
3
51-60
-
213
Hughes J R, Gust S W, Skoog K. et al .
Symptoms of tobacco withdrawal. A replication and extension.
Arch Gen Psychiatry.
1991;
48
52-59
-
214
Pisinger C, Jorgensen T.
Weight concerns and smoking in a general population: the Inter99 study.
Prev Med.
2007;
44
283-289
-
215
Nordstrom B L, Kinnunen T, Utman C H. et al .
Long-term effects of nicotine gum on weight gain after smoking cessation.
Nicotine Tob Res.
1999;
1
259-268
-
216
Hays J T, Hurt R D, Rigotti N A. et al .
Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial.
Ann Intern Med.
2001;
135
423-433
-
217
Marcus B H, Albrecht A E, King T K. et al .
The efficacy of exercise as an aid for smoking cessation in women: a randomized controlled trial.
Arch Intern Med.
1999;
159
1229-1234
-
218
Kadowaki T, Watanabe M, Okayama A. et al .
Continuation of smoking cessation and following weight change after intervention in a healthy population with high smoking prevalence.
J Occup Health.
2006;
48
402-406
-
219
Lange P, Groth S, Nyboe G J. et al .
Effects of smoking and changes in smoking habits on the decline of FEV1.
Eur Respir J.
1989;
2
811-816
-
220
Simmons M S, Connett J E, Nides M A. et al .
Smoking reduction and the rate of decline in FEV1: results from the Lung Health Study.
Eur Respir J.
2005;
25
1011-1017
-
221
Sherrill D L, Enright P, Cline M. et al .
Rates of decline in lung function among subjects who restart cigarette smoking.
Chest.
1996;
109
1001-1005
-
222
Bolliger C T, Zellweger J P, Danielsson T. et al .
Influence of long-term smoking reduction on health risk markers and quality of life.
Nicotine Tob Res.
2002;
4
433-439
-
223
Tverdal A, Bjartveit K.
Health consequences of reduced daily cigarette consumption.
Tobacco Control.
2006;
15
472-480
-
224 Raupach T, Shahab L, Neubert K. et al .Implementing a hospital-based smoking cessation programme: Evidence for a learning effect. Patient Educ Couns 2008 (in press)
-
225
Wagena E J, Zeegers M P, Schayck C P van. et al .
Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease.
Drug Saf.
2003;
26
381-403
-
226 van der Meer R M, Wagena E J, Ostelo R W. et al .Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2003: CD002999
-
227
Tashkin D, Kanner R, Bailey W. et al .
Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial.
Lancet.
2001;
357
1571-1575
-
228
Tonnesen P, Mikkelsen K, Bremann L.
Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support.
Chest.
2006;
130
334-342
-
229
Wagena E J, Knipschild P G, Huibers M JH. et al .
Efficacy of Bupropion and Nortriptyline for Smoking Cessation Among People at Risk for or With Chronic Obstructive Pulmonary Disease.
Arch Intern Med.
2005;
165
2286-2292
-
230 Hering T, Bölcskei P, Storz C. et al .Strukturierte Raucherberatung und Tabakentwöhnung - Tabakentwöhnung in der Praxis-Sprechstunde (das Tabakentwöhnungskonzept des Bundesverbandes der Pneumologen in Deutschland - BDP). In: Vorträge der 5 Deutschen Nikotin Konferenz: ed. K. Haustein. Erfurt: Deutsche Gesellschaft für Nikotinforschung 2002: 121-124
-
231 Moher M, Hey K, Lancaster T. Workplace interventions for smoking cessation. Cochrane Database Syst Rev 2005: CD003440
-
232
Twardella D, Brenner H.
Effects of practitioner education, practitioner payment and reimbursement of patients' drug costs on smoking cessation in primary care: a cluster randomised trial.
Tobacco Control.
2007;
16
15-21
-
233 Silagy C, Lancaster T, Stead L. et al .Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004: CD000146
-
234 Organization WH .Regulation of Nicotine Replacement Therapies: An Expert Consensus. Copenhagen: Regional Office for Europe 2001
-
235
Gonzales D, Rennard S I, Nides M. et al .
Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
Jama.
2006;
296
47-55
-
236
Nides M, Oncken C, Gonzales D. et al .
Smoking cessation with varenicline, a selective α4β2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
Arch Intern Med.
2006;
166
1561-1568
-
237
Oncken C, Gonzales D, Nides M. et al .
Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.
Arch Intern Med.
2006;
166
1571-1577
-
238
Tonstad S, Tonnesen P, Hajek P. et al .
Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial.
Jama.
2006;
296
64-71
-
239
Jorenby D E, Hays J T, Rigotti N A. et al .
Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.
Jama.
2006;
296
56-63
-
240 Cahill K, Stead L F, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2007: CD006103
-
241 Gourlay S G, Stead L F, Benowitz N L. Clonidine for smoking cessation. Cochrane Database Syst Rev 2004: CD000058
-
242 Bundeszentrale für gesundheitliche Aufklärung (BzgA) .Kriterien guter Praxis in der Gesundheitsförderung bei sozial Benachteiligten. Köln 2005
-
243
Morgan W J.
Maternal smoking and infant lung function. Further evidence for an in utero effect.
Am J Respir Crit Care Med.
1998;
158
689-690
-
244
Ruff L K, Volmer T, Nowak D. et al .
The economic impact of smoking in Germany.
Eur Respir J.
2000;
16
385-390
-
245
Parrott S, Godfrey C, Raw M.
Costs of employee smoking in the workplace in Scotland.
Tob Control.
2000;
9
187-192
-
246
Murray R P, Connett J E, Rand C S. et al .
Persistence of the effect of the Lung Health Study (LHS) smoking intervention over eleven years.
Prev Med.
2002;
35
314-319
-
247
Raupach T, Shahab L, Neubert K. et al .
Implementing a hospital-based smoking cessation programme: Evidence for a learning effect.
Patient Educ Couns.
2008;
70
199-204
-
248
Tengs T O, Adams M E, Pliskin J S. et al .
Five-hundred life-saving interventions and their cost-effectiveness.
Risk Anal.
1995;
15
369-390
-
249
Thomas R, Perera R.
School-based programmes for preventing smoking.
Cochrane Database Syst Rev.
2006;
3
CD001293
-
250 Secker-Walker R H, Gnich W, Platt S. et al .Community interventions for reducing smoking among adults. Cochrane Database Syst Rev 2002: CD001745
-
251 Stead L F, Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev 2005: CD001007
Prof. Dr. Stefan Andreas
Lungenfachklinik Immenhausen
Robert Koch-Straße 3
34376 Immenhausen
Email: sandreas@lungenfachklinik-immenhausen.de
